What is Acura Pharmaceuticals, Inc. (ACUR)?

Acura Pharmaceuticals, Inc. (ACUR) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of ACUR?

The current price of ACUR is $0.00. Prices are updated in real time on Stocks360.

What is ACUR's price-to-earnings (PE) ratio?

ACUR's trailing twelve-month PE ratio is -0.01, based on current price and earnings per share data available on Stocks360.

What is ACUR's market capitalization?

ACUR's market capitalization is $13,200.00, placing it in the small-cap tier.

Acura Pharmaceuticals, Inc. (ACUR)

Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic

$0.00

Market Cap

$13.20K

PE (TTM)

-0.01

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-3.29

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.01

Avg Volume

N/A

Volume

400.00

Acura Pharmaceuticals, Inc. (ACUR) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $13.20K. Trailing PE -0.01. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $0.00 2026-10-26 · $0.00 (-60.00%)

Earnings

Most Recent

Aug 14, 2017

EPS $-0.18 vs est. $-0.11

Missed by $0.07

Proprietary Signals

Signal snapshot temporarily unavailable.

About Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to exploring, developing, and bringing to market novel technologies and products aimed at enhancing medication safety across the United States. Its product portfolio features Oxaydo tablets, a potent Schedule II narcotic prescribed for managing both acute and chronic moderate-to-severe pain. The company also offers the Nexafed line, consisting of pseudoephedrine and acetaminophen tablets, widely utilized as nasal decongestants in a range of over-the-counter and prescription formulations for cold, sinus, and allergy relief. Beyond its current offerings, Acura is actively advancing six additional opioid products through various stages of formulation development. To support its global reach, Acura Pharmaceuticals maintains strategic collaboration and licensing agreements with Egalet US, Inc. and Egalet Ltd. for the worldwide production and commercialization of its Oxaydo products. Furthermore, it has established a development and commercialization partnership with Abuse Deterrent Pharma, LLC to create LTX-03, an immediate-release tablet leveraging the proprietary LIMITx technology. Established in 1935, the c…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.01×
P/S (TTM)	0.01×
P/B	0.05×
PEG	0.00×
P/FCF (TTM)	-0.02×
EV / EBITDA	-0.25×
EV / Sales	0.09×
Earnings Yield	-10000.00%
Free Cash Flow Yield	-5621.21%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$148.20K
Revenue (TTM)	$1.56M
Net Income (TTM)	-$1.32M
Free Cash Flow (TTM)	-$542.00K
Net Debt	$135.00K
Working Capital	-$143.00K
Gross Margin	94.24%
Operating Margin	-77.67%
Net Margin	-56.24%
Return on Equity	30.77%
Return on Invested Capital	-321.16%